February 4, 2021 -- Thermo Fisher has signed a marketing agreement with Chinese firm JW Therapeutics to supply that company with its Gibco CTS Dynabeads CD3/CD28. The agreement will support the development and manufacturing of chimeric antigen receptor (CAR) T therapies in China.
The agreement includes the development and commercial manufacturing of JW Therapeutics' relmacabtagene autoleucel ("relma-cel"), an anti-CD19 CAR T therapy for B-cell lymphoma. China's National Medical Products Administration has accepted JW Therapeutics' new drug application for relma-cell.
Thermo Fisher's CTS Dynabeads are part of its cell therapy systems portfolio, which is designed to mitigate manufacturing workflow challenges that cell therapy developers may encounter, the company said. The combination of anti-CD3 and anti-CD28 antibodies on Dynabeads is intended for ex vivo isolation, activation, and expansion of human T cells.